Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-4: Cetuximab Rechallenge in mCRC
NCT02934529Phase 3Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Mar 2015
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of KL-140 in metastatic colorectal cancer (mCRC) (4 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Overall Survival up to 55 months. Started Mar 2015; status: completed.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02934529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934529.